false
0001739940
0001739940
2023-12-10
2023-12-10
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED STATES
SECURITIES AND EXCHANGE
COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or
15(d) of the
Securities Exchange Act of
1934
Date of Report (Date of earliest
event reported) December 10, 2023
The Cigna Group
(Exact name of registrant
as specified in its charter)
|
Delaware
(State or other jurisdiction of
incorporation) |
001-38769
(Commission File Number) |
82-4991898
(IRS Employer
Identification No.) |
900 Cottage Grove Road
Bloomfield, Connecticut 06002
(Address of principal executive
offices) (Zip Code)
Registrant’s telephone
number, including area code:
(860) 226-6000
Not Applicable
(Former name or former address,
if changed since last report)
Check the appropriate box below if the Form 8-K
filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐ Written communications pursuant to
Rule 425 under the Securities Act (17 CFR 230.425)
☐ Soliciting material pursuant to Rule
14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐ Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐ Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b)
of the Act:
| Title of each class |
Trading Symbol(s) |
Name of each exchange on which registered |
| Common Stock, Par Value $0.01 |
CI |
New York Stock Exchange, Inc. |
Indicate by check mark whether the registrant
is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities
Exchange Act of 1934 (17 CFR §240.12b-2).
Emerging growth company ☐
If an emerging growth company, indicate by check
mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting
standards provided pursuant to Section 13(a) of the Exchange Act. ☐
| Item 7.01 |
Regulation FD Disclosure. |
2023 Outlook Affirmation
On December 10, 2023,
The Cigna Group (the “Company” or “our”) reaffirmed projected full year 2023 consolidated adjusted income from
operations on a per share basis of at least $24.75 per share and targeted consolidated adjusted income from operations on a per share
basis of at least $28.00 for full-year 2024.
The Cigna Group previously
discussed its full year 2023 outlook in its press release and investor presentation dated November 2, 2023, and during the related investor
conference call. The press release, presentation and the conference call transcript are available in the Investor Relations section of
The Cigna Group’s website located at www.thecignagroup.com. Forward-looking statements in these documents and the related call speak
only as of the date they were made.
Adjusted income (loss)
from operations is a principal financial measure of profitability used by The Cigna Group’s management because it presents the underlying
results of operations of the Company’s businesses and permits analysis of trends in underlying revenue, expenses and shareholders’
net income. Adjusted income from operations is defined as shareholders’ net income (or income before taxes less pre-tax income (loss)
attributable to noncontrolling interests for the segment metric) excluding net realized investment results, amortization of acquired intangible
assets and special items. The Cigna Group’s share of certain realized investment results of its joint ventures reported in the Cigna
Healthcare segment using the equity method of accounting are also excluded. Special items are matters that management believes are not
representative of the underlying results of operations due to their nature or size. Adjusted income (loss) from operations is measured
on an after-tax basis for consolidated results and on a pre-tax basis for segment results. Consolidated adjusted income (loss) from operations
is not determined in accordance with GAAP and should not be viewed as a substitute for the most directly comparable GAAP measure, shareholders’
net income.
Management is not
able to provide a reconciliation of adjusted income from operations to shareholders’ net income (including on a per share basis)
on a forward-looking basis because we are unable to predict, without unreasonable effort, certain components thereof including (i) future
net realized investment results (from equity method investments with respect to adjusted revenues) and (ii) future special items. These
items are inherently uncertain and depend on various factors, many of which are beyond our control. As such, any associated estimate and
its impact on shareholders’ net income could vary materially.
This information shall
not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”),
or incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act whether made before or after
the date of this report, except as shall be expressly set forth by specific reference in such a filing.
Share Repurchase
On December 10, 2023, the Company issued a
press release announcing that the Board of Directors approved an aggregate increase
of $10 billion in incremental share repurchase authorization, bringing the Company's total share repurchase authority to $11.3 billion.
The Company intends to use the majority of its discretionary cash flow for share repurchase in 2024. The Company expects this to
include repurchase of at least $5 billion of common stock between now and the end of the first half of 2024, with a portion of this repurchase
to be executed via an accelerated share repurchase program conducted in the first quarter of 2024.
The
Company’s proposed repurchases under the updated share repurchase program may be made from time to time on the open market
at prevailing market prices, through accelerated share repurchase agreements, in privately negotiated transactions, in block trades, and/or
through other legally permissible means, depending on market conditions and in accordance with applicable rules and regulations and its
insider trading policy. The timing and actual number of shares repurchased will depend on a variety of factors,
including price, general business and market conditions, and alternate uses of capital. The program may be suspended or discontinued at
any time.
The press release is furnished
as Exhibit 99.1 to this Current Report on Form 8-K and incorporated herein by reference.
This information shall not be
deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”),
or incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act whether made before or after
the date of this Current Report on Form 8-K, except as shall be expressly set forth by specific reference in such a filing.
CAUTIONARY NOTE REGARDING
FORWARD-LOOKING STATEMENTS
This Current Report on Form 8-K (the “Report”), and oral statements made with respect to information contained in this Report,
may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements
are based on The Cigna Group's current expectations and projections about future trends, events and uncertainties. These statements are
not historical facts. Forward-looking statements may include, among others, statements concerning our projected adjusted income from operations
outlook for 2023 on a consolidated, per share, and segment basis; targeted adjusted income from operations outlook for 2024 on a per share
basis; projected weighted average shares outstanding; future share repurchase and future dividends; future financial or operating performance,
including our ability to improve the health and vitality of those we serve; future growth, business strategy and strategic or operational
initiatives; economic, regulatory or competitive environments, particularly with respect to the pace and extent of change in these areas
and the impact of developing inflationary and interest rate pressures; financing or capital deployment plans and amounts available for
future deployment; our prospects for growth in the coming years; strategic transactions; expectations related to our Medicare Advantage
Capitation Rates; and other statements regarding The Cigna Group’s future beliefs, expectations, plans, intentions, liquidity, cash
flows, financial condition or performance. You may identify forward-looking statements by the use of words such as “believe,”
“expect,” “project,” “plan,” “intend,” “anticipate,” “estimate,”
“predict,” “potential,” “may,” “should,” “will” or other words or expressions
of similar meaning, although not all forward-looking statements contain such terms.
Forward-looking
statements are subject to risks and uncertainties, both known and unknown, that could cause actual results to differ materially from those
expressed or implied in forward-looking statements. Such risks and uncertainties include, but are not limited to: our ability to achieve
our strategic and operational initiatives; our ability to execute the contemplated share repurchases, including the contemplated accelerated
share repurchase program, on attractive terms, on the anticipated timing or at all; our ability to adapt to changes in an evolving and
rapidly changing industry; our ability to compete effectively, differentiate our products and services from those of our competitors and
maintain or increase market share; price competition, inflation and other pressures that could compress our margins or result in premiums
that are insufficient to cover the cost of services delivered to our customers; the potential for actual claims to exceed our estimates
related to expected medical claims; our ability to develop and maintain satisfactory relationships with physicians, hospitals, other health
service providers and with producers and consultants; our ability to maintain relationships with one or more key pharmaceutical manufacturers
or if payments made or discounts provided decline; changes in the pharmacy provider marketplace or pharmacy networks; changes in drug
pricing or industry pricing benchmarks; our ability to invest in and properly maintain our information technology and other business systems;
our ability to prevent or contain effects of a potential cyberattack or other privacy or data security incident; political, legal, operational,
regulatory, economic and other risks that could affect our multinational operations, including currency exchange rates; risks related
to strategic transactions and realization of the expected benefits of such transactions, as well as integration or separation difficulties
or underperformance relative to expectations; dependence on success of relationships with third parties; risk of significant disruption
within our operations or among key suppliers or third parties; potential liability in connection with managing medical practices and operating
pharmacies, onsite clinics and other types of medical facilities; the substantial level of government regulation over our business and
the potential effects of new laws or regulations or changes in existing laws or regulations; uncertainties surrounding participation in
government-sponsored programs such as Medicare; the outcome of litigation, regulatory audits and investigations; compliance with applicable
privacy, security and data laws, regulations and standards; potential failure of our prevention, detection and control systems; unfavorable
economic and market conditions, the risk of a recession or other economic downturn and resulting impact on employment metrics, stock market
or changes in interest rates and risks related to a downgrade in financial strength ratings of our insurance subsidiaries; the impact
of our significant indebtedness and the potential for further indebtedness in the future; credit risk related to our reinsurers; as well
as more specific risks and uncertainties discussed in our most recent report on Form 10-K and subsequent report on Forms 10-Q and 8-K
available through the Investor Relations section of www.thecignagroup.com. You should not place undue reliance on forward-looking statements,
which speak only as of the date they are made, are not guarantees of future performance or results, and are subject to risks, uncertainties
and assumptions that are difficult to predict or quantify. The Cigna Group undertakes no obligation to update or revise any forward-looking
statement, whether as a result of new information, future events or otherwise, except as may be required by law.
SIGNATURE
Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| |
THE CIGNA GROUP |
| |
|
|
| Date: December 11, 2023 |
By: |
/s/ Brian C. Evanko |
| |
|
Brian C. Evanko |
| |
|
Executive Vice President and Chief Financial Officer |
Exhibit 99.1
The Cigna Group Announces Significant Increase
to Share Repurchase Program of $10 Billion
Intends to Repurchase at
Least $5 Billion of Common Stock by End of First Half of 2024,
with Portion Executed Via ASR in First Quarter 2024
Reaffirms Previously Provided
Outlook for Full-Year 2023
BLOOMFIELD, Conn., Dec. 10, 2023 /PRNewswire/ -- Global
health company The Cigna Group (NYSE: CI) today announced that its Board of Directors has approved an aggregate increase of $10 billion
in incremental share repurchase authorization, bringing the company's total share repurchase authority to $11.3 billion. The company intends
to use the majority of its discretionary cash flow for share repurchase in 2024. The company expects this to include repurchase of at
least $5 billion of common stock between now and the end of the first half of 2024, with a portion of this repurchase to be executed via
an accelerated share repurchase program conducted in the first quarter of 2024.
"We believe Cigna's shares are significantly
undervalued and repurchases represent a value-enhancing deployment of capital as we work to support high-quality care, improved affordability,
and better health outcomes," said David M. Cordani, Chairman and Chief Executive Officer, The Cigna Group. "As we look at the
broader landscape and the strategic opportunities before us, we will remain financially disciplined with a clear focus on executing against
our strategy, delivering value for our shareholders, and investing in our future. In light of the current environment, we will consider
bolt-on acquisitions aligned with our strategy, as well as value-enhancing divestitures."
In connection with today's announcement, Cigna
reaffirmed its previously provided outlook of full-year 2023 consolidated adjusted income from operations on a per share basis of at least
$24.75 per share. The company continues to target consolidated adjusted income from operations on a per share basis of at least $28 for
full-year 2024.
Added Cordani, "Over the past 10 years, our
consistent execution has resulted in EPS growth of more than 13 percent on an annualized basis, demonstrating our ability to profitably
evolve our business and the services we provide. We are confident in the ongoing growth and strength of Cigna's businesses and expect
to carry significant momentum forward into 2024. This conviction reinforces the confidence we have in achieving our long-term annual adjusted
EPS growth target of 10-13% while maintaining an attractive dividend."
The company's proposed repurchases under the updated
share repurchase program may be made from time to time on the open market at prevailing market prices, through accelerated share repurchase
agreements, in privately negotiated transactions, in block trades, and/or through other legally permissible means, depending on market
conditions and in accordance with applicable rules and regulations and its insider trading policy.
Forward-Looking Statements
This press release, and oral statements made in
connection with this release, may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act
of 1995. Forward-looking statements are based on The Cigna Group's current expectations and projections about future trends, events and
uncertainties. These statements are not historical facts. Forward-looking statements may include, among others, statements concerning
our projected adjusted income from operations outlook for 2023 on a consolidated, per share, and segment basis; targeted adjusted income
from operations outlook for 2024 on a per share basis; projected weighted average shares outstanding; future share repurchase and future
dividends; future financial or operating performance, including our ability to improve the health and vitality of those we serve; future
growth, business strategy and strategic or operational initiatives; economic, regulatory or competitive environments, particularly with
respect to the pace and extent of change in these areas and the impact of developing inflationary and interest rate pressures; financing
or capital deployment plans and amounts available for future deployment; our prospects for growth in the coming years; strategic transactions;
expectations related to our Medicare Advantage Capitation Rates; and other statements regarding The Cigna Group's future beliefs, expectations,
plans, intentions, liquidity, cash flows, financial condition or performance. You may identify forward-looking statements by the use of
words such as "believe," "expect," "project," "plan," "intend," "anticipate,"
"estimate," "predict," "potential," "may," "should," "will" or other words
or expressions of similar meaning, although not all forward-looking statements contain such terms.
Forward-looking statements are subject to risks
and uncertainties, both known and unknown, that could cause actual results to differ materially from those expressed or implied in forward-looking
statements. Such risks and uncertainties include, but are not limited to: our ability to achieve our strategic and operational initiatives;
our ability to execute the contemplated share repurchases, including the contemplated accelerated share repurchase program, on attractive
terms, on the anticipated timing or at all; our ability to adapt to changes in an evolving and rapidly changing industry; our ability
to compete effectively, differentiate our products and services from those of our competitors and maintain or increase market share; price
competition, inflation and other pressures that could compress our margins or result in premiums that are insufficient to cover the cost
of services delivered
to our customers; the potential for actual claims to exceed our estimates related to expected medical claims; our
ability to develop and maintain satisfactory relationships with physicians, hospitals, other health service providers and with producers
and consultants; our ability to maintain relationships with one or more key pharmaceutical manufacturers or if payments made or discounts
provided decline; changes in the pharmacy provider marketplace or pharmacy networks; changes in drug pricing or industry pricing benchmarks;
our ability to invest in and properly maintain our information technology and other business systems; our ability to prevent or contain
effects of a potential cyberattack or other privacy or data security incident; political, legal, operational, regulatory, economic and
other risks that could affect our multinational operations, including currency exchange rates; risks related to strategic transactions
and realization of the expected benefits of such transactions, as well as integration or separation difficulties or underperformance relative
to expectations; dependence on success of relationships with third parties; risk of significant disruption within our operations or among
key suppliers or third parties; potential liability in connection with managing medical practices and operating pharmacies, onsite clinics
and other types of medical facilities; the substantial level of government regulation over our business and the potential effects of new
laws or regulations or changes in existing laws or regulations; uncertainties surrounding participation in government-sponsored programs
such as Medicare; the outcome of litigation, regulatory audits and investigations; compliance with applicable privacy, security and data
laws, regulations and standards; potential failure of our prevention, detection and control systems; unfavorable economic and market conditions,
the risk of a recession or other economic downturn and resulting impact on employment metrics, stock market or changes in interest rates
and risks related to a downgrade in financial strength ratings of our insurance subsidiaries; the impact of our significant indebtedness
and the potential for further indebtedness in the future; credit risk related to our reinsurers; as well as more specific risks and uncertainties
discussed in our most recent report on Form 10-K and subsequent reports on Forms 10-Q and 8-K available through the Investor Relations
section of www.thecignagroup.com. You should not place undue reliance on forward-looking statements, which speak only as of the date they
are made, are not guarantees of future performance or results, and are subject to risks, uncertainties and assumptions that are difficult
to predict or quantify. The Cigna Group undertakes no obligation to update or revise any forward-looking statement, whether as a result
of new information, future events or otherwise, except as may be required by law.
Notes:
- Adjusted income (loss) from operations is a principal
financial measure of profitability used by The Cigna Group's management because it presents the underlying results of operations
of the Company's businesses and permits analysis of trends in underlying revenue, expenses and shareholders' net income. Adjusted income
from operations is defined as shareholders' net income (or income before taxes less pre-tax income (loss) attributable to noncontrolling
interests for the segment metric) excluding net realized investment results, amortization of acquired intangible assets and special items.
The Cigna Group's share of certain realized investment results of its joint ventures reported in the Cigna Healthcare segment using the
equity method of accounting are also excluded. Special items are matters that management believes are not representative of the underlying
results of operations due to their nature or size. Adjusted income (loss) from operations is measured on an after-tax basis for consolidated
results and on a pre-tax basis for segment results. Consolidated adjusted income (loss) from operations is not determined in accordance
with GAAP and should not be viewed as a substitute for the most directly comparable GAAP measure, shareholders' net income.
- Management is not able to provide a reconciliation
of adjusted income from operations to shareholders' net income (including on a per share basis (EPS)) or adjusted revenues to total revenues
on a forward-looking basis because we are unable to predict, without unreasonable effort, certain components thereof including (i) future
net realized investment results (from equity method investments with respect to adjusted revenues) and (ii) future special items. These
items are inherently uncertain and depend on various factors, many of which are beyond our control. As such, any associated estimate and
its impact on shareholders' net income and total revenue could vary materially.
INVESTOR RELATIONS CONTACT:
Ralph Giacobbe
860-787-7968
Ralph.Giacobbe@TheCignaGroup.com
MEDIA CONTACT:
Justine Sessions
860-810-6523
Justine.Sessions@Evernorth.com
v3.23.3
| X |
- DefinitionBoolean flag that is true when the XBRL content amends previously-filed or accepted submission.
| Name: |
dei_AmendmentFlag |
| Namespace Prefix: |
dei_ |
| Data Type: |
xbrli:booleanItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionFor the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.
| Name: |
dei_DocumentPeriodEndDate |
| Namespace Prefix: |
dei_ |
| Data Type: |
xbrli:dateItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionThe type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.
| Name: |
dei_DocumentType |
| Namespace Prefix: |
dei_ |
| Data Type: |
dei:submissionTypeItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionAddress Line 1 such as Attn, Building Name, Street Name
| Name: |
dei_EntityAddressAddressLine1 |
| Namespace Prefix: |
dei_ |
| Data Type: |
xbrli:normalizedStringItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- Definition
+ References
+ Details
| Name: |
dei_EntityAddressCityOrTown |
| Namespace Prefix: |
dei_ |
| Data Type: |
xbrli:normalizedStringItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionCode for the postal or zip code
| Name: |
dei_EntityAddressPostalZipCode |
| Namespace Prefix: |
dei_ |
| Data Type: |
xbrli:normalizedStringItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionName of the state or province.
| Name: |
dei_EntityAddressStateOrProvince |
| Namespace Prefix: |
dei_ |
| Data Type: |
dei:stateOrProvinceItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionA unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK. Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection b-2
| Name: |
dei_EntityCentralIndexKey |
| Namespace Prefix: |
dei_ |
| Data Type: |
dei:centralIndexKeyItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionIndicate if registrant meets the emerging growth company criteria. Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection b-2
| Name: |
dei_EntityEmergingGrowthCompany |
| Namespace Prefix: |
dei_ |
| Data Type: |
xbrli:booleanItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionCommission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.
| Name: |
dei_EntityFileNumber |
| Namespace Prefix: |
dei_ |
| Data Type: |
dei:fileNumberItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionTwo-character EDGAR code representing the state or country of incorporation.
| Name: |
dei_EntityIncorporationStateCountryCode |
| Namespace Prefix: |
dei_ |
| Data Type: |
dei:edgarStateCountryItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionThe exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC. Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection b-2
| Name: |
dei_EntityRegistrantName |
| Namespace Prefix: |
dei_ |
| Data Type: |
xbrli:normalizedStringItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionThe Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS. Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection b-2
| Name: |
dei_EntityTaxIdentificationNumber |
| Namespace Prefix: |
dei_ |
| Data Type: |
dei:employerIdItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionLocal phone number for entity.
| Name: |
dei_LocalPhoneNumber |
| Namespace Prefix: |
dei_ |
| Data Type: |
xbrli:normalizedStringItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act. Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 13e
-Subsection 4c
| Name: |
dei_PreCommencementIssuerTenderOffer |
| Namespace Prefix: |
dei_ |
| Data Type: |
xbrli:booleanItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act. Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 14d
-Subsection 2b
| Name: |
dei_PreCommencementTenderOffer |
| Namespace Prefix: |
dei_ |
| Data Type: |
xbrli:booleanItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionTitle of a 12(b) registered security. Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection b
| Name: |
dei_Security12bTitle |
| Namespace Prefix: |
dei_ |
| Data Type: |
dei:securityTitleItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionName of the Exchange on which a security is registered. Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection d1-1
| Name: |
dei_SecurityExchangeName |
| Namespace Prefix: |
dei_ |
| Data Type: |
dei:edgarExchangeCodeItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act. Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Section 14a
-Number 240
-Subsection 12
| Name: |
dei_SolicitingMaterial |
| Namespace Prefix: |
dei_ |
| Data Type: |
xbrli:booleanItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionTrading symbol of an instrument as listed on an exchange.
| Name: |
dei_TradingSymbol |
| Namespace Prefix: |
dei_ |
| Data Type: |
dei:tradingSymbolItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act. Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Securities Act
-Number 230
-Section 425
| Name: |
dei_WrittenCommunications |
| Namespace Prefix: |
dei_ |
| Data Type: |
xbrli:booleanItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
Cigna (NYSE:CI)
과거 데이터 주식 차트
부터 4월(4) 2024 으로 5월(5) 2024
Cigna (NYSE:CI)
과거 데이터 주식 차트
부터 5월(5) 2023 으로 5월(5) 2024
